Individualizing Inpatient Diabetes Management During the Coronavirus Disease 2019 Pandemic
Diabetes is associated with poor clinical outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19). During this pandemic, many hospitals have already become overwhelmed around the world and are rapidly entering crisis mode. While there are global efforts to boost personal protective equipment (PPE) production, many centers are improvising care strategies, including the implementation of technology to prevent healthcare workers' exposures and reduce the waste of invaluable PPE. Not optimizing glycemic control due to clinical inertia driven by fear or lack of supplies may lead to poor outcomes in patients with diabetes and COVID-19. Individualized care strategies, novel therapeutic regimens, and the use of diabetes technology may reduce these barriers. However, systematic evaluation of these changes in care is necessary to evaluate both patient- and community-centered outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Journal of diabetes science and technology - 14(2020), 4 vom: 18. Juli, Seite 705-707 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pasquel, Francisco J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 21.07.2020 Date Revised 07.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/1932296820923045 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309540828 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309540828 | ||
| 003 | DE-627 | ||
| 005 | 20231225134133.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/1932296820923045 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1031.xml |
| 035 | |a (DE-627)NLM309540828 | ||
| 035 | |a (NLM)32370606 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pasquel, Francisco J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Individualizing Inpatient Diabetes Management During the Coronavirus Disease 2019 Pandemic |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2020 | ||
| 500 | |a Date Revised 07.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Diabetes is associated with poor clinical outcomes in hospitalized patients with coronavirus disease 2019 (COVID-19). During this pandemic, many hospitals have already become overwhelmed around the world and are rapidly entering crisis mode. While there are global efforts to boost personal protective equipment (PPE) production, many centers are improvising care strategies, including the implementation of technology to prevent healthcare workers' exposures and reduce the waste of invaluable PPE. Not optimizing glycemic control due to clinical inertia driven by fear or lack of supplies may lead to poor outcomes in patients with diabetes and COVID-19. Individualized care strategies, novel therapeutic regimens, and the use of diabetes technology may reduce these barriers. However, systematic evaluation of these changes in care is necessary to evaluate both patient- and community-centered outcomes | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a diabetes | |
| 650 | 4 | |a hospitalized | |
| 650 | 4 | |a hyperglycemia | |
| 650 | 4 | |a inpatient | |
| 650 | 7 | |a Insulin |2 NLM | |
| 700 | 1 | |a Umpierrez, Guillermo E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes science and technology |d 2007 |g 14(2020), 4 vom: 18. Juli, Seite 705-707 |w (DE-627)NLM179163914 |x 1932-2968 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:4 |g day:18 |g month:07 |g pages:705-707 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/1932296820923045 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 4 |b 18 |c 07 |h 705-707 | ||